Skip to main content
Choose your country to see content specific to that location
Global - English flag
Global - English
  • Global flag
    Global
    • English
  • Australia flag
    Australia
    • English
  • Austria flag
    Austria
    • Deutsch
    • English
  • Canada flag
    Canada
    • English
    • Français
  • Czech Republic flag
    Czech Republic
    • Čeština
    • English
  • France flag
    France
    • Français
    • English
  • Germany flag
    Germany
    • Deutsch
    • English
  • Italy flag
    Italy
    • Italiano
    • English
  • Poland flag
    Poland
    • Polski
    • English
  • Singapore flag
    Singapore
    • English
  • Spain flag
    Spain
    • Español
    • English
  • Sweden flag
    Sweden
    • Svenska
    • English
  • Switzerland flag
    Switzerland
    • Deutsch
    • Français
    • Italiano
    • English
  • United Kingdom flag
    United Kingdom
    • English
  • Science & technology
    Science & technology

    Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.

    • Overview
    • Our pipeline
    • Matrix-M™ adjuvant
    • Recombinant, protein-based nanoparticle vaccine
    • Global vaccine approval/authorization map
    COVID-19 UPDATES

    Novavax has demonstrated its ability to quickly develop viable vaccine candidates for emerging infectious diseases such as COVID-19.

    Learn more about our COVID-19 updates
  • Who we are
    Who we are

    We are a biotechnology company committed to help address serious infectious diseases globally through the discovery and development of innovative vaccines to patients around the world.

    • Our company
    • Our team
    • Our partners
    • Our commitments
    • Our transparency commitment
    Build your future with us

    Join other passionately curious people who are bringing innovative vaccines to the world

    Discover career opportunities
  • Insights
    Insights

    Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.

    • Articles
    • Why do we need an updated XBB vaccine?
    • Diversity matters: Inclusivity in clinical trials
    • From pandemic to endemic: Why COVID-19 may be here to stay
    • Standing on the shoulders of giants: How a Novavax vaccine is developed
Novavax
  • Medical professionals
  • News & media
  • Investors
  • Careers
Novavax
Global - English flag
Global - English
  • Global flag
    Global
    • English
  • Australia flag
    Australia
    • English
  • Austria flag
    Austria
    • Deutsch
    • English
  • Canada flag
    Canada
    • English
    • Français
  • Czech Republic flag
    Czech Republic
    • Čeština
    • English
  • France flag
    France
    • Français
    • English
  • Germany flag
    Germany
    • Deutsch
    • English
  • Italy flag
    Italy
    • Italiano
    • English
  • Poland flag
    Poland
    • Polski
    • English
  • Singapore flag
    Singapore
    • English
  • Spain flag
    Spain
    • Español
    • English
  • Sweden flag
    Sweden
    • Svenska
    • English
  • Switzerland flag
    Switzerland
    • Deutsch
    • Français
    • Italiano
    • English
  • United Kingdom flag
    United Kingdom
    • English
  • Science & technology
    • Overview
    • Our pipeline
    • Matrix-M™ adjuvant
    • Recombinant, protein-based nanoparticle vaccine
    • Global vaccine approval/authorization map
  • Who we are
    • Our company
    • Our team
    • Our partners
    • Our commitments
    • Our transparency commitment
  • Insights
    • Articles
    • Why do we need an updated XBB vaccine?
    • Diversity matters: Inclusivity in clinical trials
    • From pandemic to endemic: Why COVID-19 may be here to stay
    • Standing on the shoulders of giants: How a Novavax vaccine is developed
  • Medical professionals
  • News & media
  • Investors
  • Careers

Sitemap

Home
Science & Technology
Overview
Our pipeline
Matrix-M™ adjuvant
Recombinant protein-based nanoparticle vaccine
Global vaccine authorization / approval map
Who we are
Our company
Executive leadership
Board of directors
Our partners
Insights
Overview
Diversity matters: Inclusivity in clinical trials
Why do we need vaccine booster injections?
From pandemic to endemic: Why COVID-19 may be here to stay
Understanding vaccine safety and efficacy in clinical trials
Standing on the shoulders of giants: How a Novavax vaccine is developed
Creating vaccines to help fight constantly changing threats
Statement on Novavax commitment to equitable access and transparency
Audience centric hub
Medical professionals
News & media
Investors
Careers
Help center
Contact us
Email us
Call us
Legal
Privacy policy
Cookies policy
Terms & conditions
Novavax. Creating tomorrow's vaccines today.

Science & technology

  • Overview
  • Our pipeline
  • Recombinant nanoparticle vaccine technology
  • Matrix-M™ adjuvant technology
  • Global vaccine approval/authorization map

Who we are

  • Our company
  • Executive leadership
  • Board of directors
  • Our partners
  • Our commitments
  • Our transparency commitment

More information

  • Global authorization site for Novavax COVID-19 Vaccine (recombinant, adjuvanted)
  • Global medical information site
  • Ask medical or scientific questions about our product, report adverse events, and product quality complaints
  • Expanded access policy

Contact us

  • Connect with us
  • Sign up for updates
  • Social media guidelines

Careers

55Current opportunities

Novavax is proud to be recognized by the 2021 Top Workplaces USA, reflecting our dedication to an exceptional work culture

Explore current opportunities in:

  • USA flag
    USA
  • CZ flag
    CZ
  • SE flag
    SE
  • EUR flag
    EUR
  • APAC flag
    APAC
TOP WORK PLACES 2021. USA. TOP WORKPLACE FOR 2021 By Energage
© 2023 Novavax. All rights reserved.
  • Privacy Policy
  • Cookies Policy
  • Terms and Conditions
  • Site Map
  • Pay Transparency Nondiscrimination Provision
  • Purchase Order Terms and Conditions
You are leaving novavax.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Novavax provides this link as a service to website visitors. Novavax is not responsible for the privacy policy of any third-party websites.

Continue
Cancel
This Novavax website is for medical professionals only.

Click "Continue" only if you are a medical professional.

Continue
Cancel
You are leaving novavax.com

You have selected a link that will take you to a site maintained by a third party. Novavax is not responsible for the Privacy Policy of any third-party websites.

Continue
Cancel
DISCLAIMER:

The information provided on this website is intended for members of the general public in only.

Continue
Cancel
Thanks for your interest in Novavax. The following website is intended exclusively for healthcare professionals and Novavax shareholders.

Please confirm below so we may provide you with the most appropriate information.

I'm a healthcare professional or shareholder
I am a member of the general public